bih.button.backtotop.text
BROWSE BY TEST NAME
#
%
1
2
3
5
8
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code (รหัสการทดสอบ):
090-30-2620

Order Name (ชื่อการทดสอบ):
Methotrexate (Blood)

 
Specimen / Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 4:00 Hours
 
Useful For (ประโยชน์การทดสอบ):
  • Determination of methotrexate in human serum.
  • Used in monitoring levels of methotrexate to ensure appropriate therapy.
 
Methodology (วิธีการทดสอบ):
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
AliasesName (ชื่อเรียกอื่นๆ) :
MTX (Methotrexate), Blood
 
 
 
Test Code (รหัสการทดสอบ):
090-30-2620

Order Name (ชื่อการทดสอบ):
Methotrexate (Blood)

 
Collection Specimen Or Container (สิ่งส่งตรวจ/ภาชนะ):
Blood/ Plain Blood (Red Top) 6 mL, 1 tube
 
Specimen Testing Type (สิ่งส่งตรวจที่ใช้ในการทดสอบ):
Serum, minimum volume 1 mL
 
Sub Mission Container (ภาชนะส่งตรวจ):
Plastic vial
 
Rejection Criteria (เกณฑ์ปฏิเสธสิ่งส่งตรวจ):
Hemolysis: 4+ reject
 
Specimen Stabillity (ความคงตัวของสิ่งส่งตรวจ):
Specimen Type Temperature Time
Serum (keep in original tube) Refrigerated, 2oC to 8oC 8 hours
Serum Refrigerated, 2oC to 8oC 2 days
Frozen, -20oC 14 days
 
 
 
Test Code (รหัสการทดสอบ):
090-30-2620

Order Name (ชื่อการทดสอบ):
Methotrexate (Blood)

 
Method detail (วิธีการทดสอบ):
Chemiluminescent Microparticle Immuno Assay (CMIA)
 
Schedule (ตารางการทดสอบ):
Tested Daily (24 Hours)
 
Turnaround Time (ระยะเวลารอผล):
Specimen collected to reported within 4:00 Hours
 
Performing Location (หน่วยงานที่ทำการทดสอบ):
Immunology, Laboratory Department Tel. 13227
 
Specimen Retention Time (ระยะเวลาเก็บสิ่งส่งตรวจ):
5 days
 
 
 
Test Code (รหัสการทดสอบ):
090-30-2620

Order Name (ชื่อการทดสอบ):
Methotrexate (Blood)

 
 
Clinical Information (ข้อมูลทางคลินิก):
Methotrexate (MTX, amethopterin) is a folate antimetabolite. It is an analog of aminopterin, which is also derived from folic acid. The molecular structure of methotrexate differs from folic acid in that it has a hydroxyl
group in place of the 4-amino group on the pteridine ring and there is no methyl group at the N position.
Methotrexate is an antineoplastic drug used solely or in combination with other antineoplastic drugs for the treatment of leukemia and other diseases. Relatively low doses of methotrexate have been used in the treatment of nonmalignant diseases such as severe psoriasis, asthma, rheumatoid arthritis, sarcoidosis, and transplantation therapy.

Intermediate to high doses of methotrexate with Leucovorin rescue have been used with favorable results in the treatment of osteogenic sarcoma, leukemia, non-Hodgkin’s lymphoma, lung and breast cancer. Methotrexate levels are monitored to avoid excessive toxic effects of the drug and to determine when to intervene with counter-acting ‘rescue’ therapy. Adverse reactions include myelosuppression, stomatitis, nausea,
vomiting, convulsions, liver and renal abnormalities, anemia, leukopenia, thrombocytopenia, osteoporosis, neurotoxicity, and leukoencephalopathy.

There are no current indications for monitoring low dose methotrexate therapies.
 
Reference Value (ค่าอ้างอิง):
Increased risk of toxicity.
  • Methotrexate >10 umol/L 24 hours after dose.
  • Methotrexate >1 umol/L 48 hours after dose.
  • Methotrexate >0.1 umol/L 72 hours after dose.
 
Clinical Reference (เอกสารอ้างอิง):
  1. Manufacturer’s reagent package insert, Architect® Methotrexate, ABBOTT Max-Planck-Ring 2 65205 Wiesbaden Germany, December 2014
  2. ​Reference intervals: UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Retrieved: July 2018)